Search

Search Results

• THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone

  George J Kontoghiorghes, Marios Kleanthous, Christina N. Kontoghiorghe

  e2020011

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.011

  2365

  PDF: 1573

  HTML: 609

• IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES

  Paolo Cianciulli

  e2009034

  1233

  PDF: 610

  HTML: 2311

• CARDIAC FUNCTION AND IRON CHELATION IN THALASSEMIA MAJOR AND INTERMEDIA: A REVIEW OF THE UNDERLYING PATHOPHYSIOLOGY AND APPROACH TO CHELATION MANAGEMENT

  Athanasios Aessopos, Vasilios Berdoukas

  e2009002

  2009-07-18

  1560

  PDF: 479

  HTML: 1427

• ECONOMIC EVALUATION OF CHELATION REGIMENS FOR ?--THALASSEMIA MAJOR: A SYSTEMATIC REVIEW

  Jialian Li

  e2019036

  2019-06-24

  https://doi.org/10.4084/mjhid.2019.036

  1962

  PDF: 1437

  HTML: 219

• DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA

  Ali Taher

  e2018066

  2018-11-01

  https://doi.org/10.4084/mjhid.2018.066

  2873

  PDF: 1575

  HTML: 225

• The COST-UTILITY ANALYSIS OF FOUR CHELATION REGIMENS FOR ?-THALASSEMIA MAJOR: A CHINESE PERSPECTIVE

  Jialian Li

  e2020029

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.029

  1711

  PDF: 962

  HTML: 266

• GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload

  Vincenzo De Sanctis, Ashraf Soliman, Shahina Daar, Ploutarchos Tzoulis , Salvatore Di Maio, Christos Kattamis

  e2023006

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.006

  3877

  PDF: 1088

  HTML: 425

• THE ICET-A RECOMMENDATIONS FOR THE DIAGNOSIS AND MANAGEMENT OF DISTURBANCES OF GLUCOSE HOMEOSTASIS IN THALASSEMIA MAJOR PATIENTS

  Vincenzo De Sanctis

  e2016058

  2016-10-25

  https://doi.org/10.4084/mjhid.2016.058

  4177

  PDF: 1177

  HTML: 1169

• DOES INSULIN LIKE GROWTH FACTOR-1 (IGF-1) DEFICIENCY HAVE A “PROTECTIVE” ROLE IN THE DEVELOPMENT OF DIABETIC RETINOPATHY IN THALASSEMIA MAJOR PATIENTS?

  Vincenzo De Sanctis

  e2015038

  2015-05-20

  https://doi.org/10.4084/mjhid.2015.038

  1917

  PDF: 922

  HTML: 5053

• BETA THALASSEMIA MAJOR IN A DEVELOPING COUNTRY: EPIDEMIOLOGICAL, CLINICAL AND EVOLUTIONARY ASPECT

  Mohamed Bejaoui, Naouel Guirat

  e2013002

  2013-01-01

  https://doi.org/10.4084/mjhid.2013.002

  1590

  PDF: 891

  HTML: 2470

• A Young Adult with Unintentional Acute Parenteral Iron intoxication Treated with Oral Chelation: The Use of Liver Ferriscan.

  Vincenzo De Sanctis

  e2017008

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.008

  3075

  PDF: 999

  HTML: 1641

• High Prevalence of Antiphospholipid Antibodies in Children with Non-Transfusion Dependent Thalassemia and Possible Correlations with Microparticles Antiphospholipid Antibodies and Thalassemia in children

  Jitlada Chinsuwan, Phatchanat Klaihmon, Praguywan Kadegasem, Ampaiwan Chuansumrit, Anucha Soisamrong, Kovit Pattanapanyasat, Pakawan Wongwerawattanakoon, Nongnuch Sirachainan

  e2020071

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.071

  877

  PDF: 594

  HTML: 274

• PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.

  Ariel Koren, Lora Profeta, Luci Zalman, Haya Palmor, Carina Levin, Ronit Bril Zamir, Stavit Shalev, Orna Blondheim

  e2014012

  2014-02-17

  https://doi.org/10.4084/mjhid.2014.012

  2450

  PDF: 1146

  HTML: 11790

• GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS

  Naouel GUIRAT

  e2018031

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.031

  2695

  PDF: 998

  HTML: 404

  TABLE: 182

  FIGURES: 240

• JADENU® SUBSTITUTING EXJADE® IN IRON OVERLOADED ?- THALASSEMIA MAJOR (BTM) PATIENTS: A PRELIMINARY REPORT OF THE EFFECTS ON THE TOLERABILITY, SERUM FERRITIN LEVEL, LIVER IRON CONCENTRATION AND BIOCHEMICAL PROFILES

  Vincenzo De Sanctis

  e2018064

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.064

  2574

  PDF: 1200

  HTML: 238

• FASTING PLASMA GLUCOSE LEVELS WITHIN THE HIGH NORMAL RANGE ARE ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF FUTURE DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β THALASSEMIA: A DECADE-LONG MULTICENTER RETROSPECTIVE ANALYSIS Higher normal fasting plasma glucose and glucose dysregulation in β- thalassemia

  Vincenzo De Sanctis, Forough Saki, Mehran Karimi, Mohammad Faranoush, Ihab Elhakim, Ashraf T Soliman, Shahina Daar, Ploutarchos Tzoulis

  e2025072

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.072

  612

  PDF: 214

  Html: 28

• EARLY PREDICTORS OF RENAL DYSFUNCTION IN ?-THALASSEMIA MAJOR AND INTERMEDIA PATIENTS

  Azza A.G. Tantawy, Nagham El Bablawy, Amira A. M Adly, Fatma S E Ebeid

  e2014057

  2004-09-01

  https://doi.org/10.4084/mjhid.2014.057

  1913

  PDF: 940

  HTML: 3790

• ZYGOMYCOSIS IN IMMUNOCOMPROMISED NON-HAEMATOLOGICAL PATIENTS

  George Petrikkos, Miranda Drogari-Apiranthitou

  e2011012

  2011-03-14

  https://doi.org/10.4084/mjhid.2011.012

  2782

  PDF: 936

  HTML: 7318

• POST-LOAD PLASMA GLUCOSE INCREASE (PG-GAP) AS A RISK FACTOR FOR DEVELOPING DYSGLYCEMIA IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (Β-TDT): RETROSPECTIVE ANALYSIS OVER 8 YEARS Post load plasma glucose increase and the risk of glucose dysregulation in thalassemia

  Vincenzo De Sanctis, Mohammad Faranoush, Efthymia Vlachaki, Theodora- Maria Venou, Ashraf T Soliman, Shahina Daar, Ploutarchos Tzoulis, Christos Kattamis

  e2025069

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.069

  471

  PDF: 234

  HTML: 34

• PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?

  Kalliopi Zachou, Pinelopi Arvaniti, Nikolaos K. Gatselis, Kalliopi Azariadis, Georgia Papadamou, Eirini Rigopoulou, George N. Dalekos

  e2017003

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.003

  2903

  PDF: 966

  HTML: 2056

  Cover letter: 174

• PREDISPOSING FACTORS TO INFECTIONS IN THALASSEMIA SYNDROME PATIENTS

  Eman M Mansory, Lina M. Abdulrahman, Balsam Osman, Sawsan M. Sawsan, Assil F. Ruckn, Marwa Aljedaani, Nemmat Hassan, Ahmed S. Barefah, Hatem M. Alahwal, Yassir Daghistani, Salem M. Bahashwan, Abdullah T. Almohammadi, Osman O. Radhwi

  e2025055

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.055

  1433

  PDF: 1406

  HTML: 329

• HEALTH-RELATED QUALITY OF LIFE IN THAI CHILDREN WITH THALASSEMIA AS EVALUATED BY PEDSQL AND EQ-5D-Y: A SINGLE CENTER EXPERIENCE

  Pacharapan Surapolchai, Phakatip Sinlapamongkolkul

  e2020036

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.036

  1466

  PDF: 1112

  HTML: 290

• Congenital Atypical Microcytic Anemia Accompanied by Iron Deficiency and Accumulation

  mustafa özay, zafer bıçakçı

  e2022070

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.070

  808

  PDF: 562

  HTML: 279

• INFECTIONS IN THALASSEMIA AND HEMOGLOBINOPATHIES

  Bianca Maria Ricerca, Arturo Di Girolamo, Deborah Rund

  e2009028

  2009-12-28

  1060

  PDF: 609

  HTML: 4284

• CAN WE PREDICT INCIPIENT DIABETES MELLITUS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (β-TDT) REFERRED WITH A HISTORY OF PREDIABETES? Risk factors for incipient diabetes in thalassemia

  Vincenzo De Sanctis, Ashraf Soliman, Shahina Daar, Ploutarchos Tzoulis, Christos Kattamis

  e2024005

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.005

  1029

  PDF: 1329

  HTML: 95

• VASCULAR ENDOTHELIAL GROWTH FACTOR IN CHILDREN WITH THALASSEMIA MAJOR PDF

  sameh samir fahmey, Hassan Naguib, sanna Abdelshafy, rasha Alashry

  e2013044

  2013-06-05

  https://doi.org/10.4084/mjhid.2013.044

  1291

  PDF: 852

  HTML: 1028

  Figure 1 the correlation between frequency of blood transfusion and serum vascular endothelial growth factor (VEGF).: 170

• A MULTICENTER ICET-A STUDY ON AGE AT MENARCHE AND MENSTRUAL CYCLES IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA (TDT) WHO STARTED EARLY CHELATION THERAPY WITH DIFFERENT CHELATING AGENTS. Age at menarche and menstrual cycles in patients with transfusion-dependent thalassemia.

  SALVATORE DI MAIO, VINCENZO DE SANCTIS, PIERLUIGI MARZUILLO, CHRISTOS KATTAMIS, SHAHINA DAAR, MEHERAN KARIMI, SAKI FOROUGH, ATANAS BANKEV, VALERIA KALEVA, SOTEROULA CHRISTOU, CARMELO FORTUGNO, POLYXENI DELAPORTA, ASHRAF T SOLIMAN , PLOUTARCHOS TZOULIS

  e2023058

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.058

  751

  PDF: 490

  HTML: 103

• CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.

  Vincenzo De Sanctis

  e2020006

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.006

  4201

  PDF: 1511

  HTML: 440

• Concordance Rate of Fasting Plasma Glucose (PG) and 2-hour PG post Oral Glucose Tolerance Test (OGTT) in Patients with new diagnosis of Thalassemia-Related Diabetes Mellitus (Th-RDM):Implications for Clinical Practice OGTT concordance rate in thalassemia major

  Vincenzo De Sanctis, Mohammad Faranoush, Shahina Daar, Ihab Elhakim, Ashraf T Soliman, Forough Saki, Mehran Karimi, Ploutarchos Tzoulis

  e2026011

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.011

  571

  PDF: 442

  Html: 98

• A A RETROSPECTIVE LONG-TERM STUDY ON AGE AT MENARCHE AND MENSTRUAL CHARACTERISTICS IN 85 YOUNG WOMEN WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (TDT) BORN BETWEEN 1965 AND 1995 Long-Term Study on Age at Menarche and Menstrual Characteristics in patients with TDT

  Vincenzo De Sanctis, Salvatore Di Maio

  e2021040

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.040

  1470

  PDF: 488

  HTML: 170

• INSULIN-LIKE GROWTH FACTOR-1 (IGF-1): DEMOGRAPHIC, CLINICAL AND LABORATORY DATA IN 120 CONSECUTIVE ADULT PATIENTS WITH THALASSAEMIA MAJOR

  V. De Sanctis

  e2014.074

  2014-11-01

  https://doi.org/10.4084/mjhid.2014.074

  2220

  PDF: 929

  HTML: 26933

• ACQUIRED HYPOGONADOTROPIC HYPOGONADISM (AHH) IN THALASSAEMIA MAJOR PATIENTS: AN UNDERDIAGNOSED CONDITION?

  Vincenzo De Sanctis

  e2016001

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.001

  5096

  PDF: 1281

  HTML: 3569

• INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY

  Giuseppe Leone, Livio Pagano

  e2018039

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.039

  4125

  PDF: 1443

  HTML: 587

• IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

  Elena Maria Elli, Angelo Belotti, Andrea Aroldi, Matteo Parma, Pietro Pioltelli, Enrico Maria Pogliani

  e2014042

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.042

  2089

  PDF: 1139

  HTML: 1984

• TRANSIENT ELASTOGRAPHY (TE) IS A USEFUL TOOL FOR ASSESSING THE RESPONSE OF LIVER IRON CHELATION IN SICKLE CELL DISEASE PATIENTS

  SOPHIA DELICOU

  e2018049

  2018-09-01

  https://doi.org/10.4084/mjhid.2018.049

  1504

  PDF: 798

  HTML: 182

• HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA AND SICKLE CELL DISEASE: EXPERIENCE OF MEDITERRANEAN INSTITUTE OF HEMATOLOGY IN A MULTI-ETHNIC POPULATION.

  Marco Marziali, Antonella Isgrò, Javid Gaziev, Guido Lucarelli

  e2009027

  2009-12-26

  1656

  PDF: 718

  HTML: 2908

• Late-onset male hypogonadism and fertility potential in thalassemia major patients: Two emerging issues

  Vincenzo De Sanctis

  e2015047

  2015-07-08

  https://doi.org/10.4084/mjhid.2015.047

  1759

  PDF: 924

  HTML: 779

• Does splenectomy influence the development of Hypothyroidism in Transfusion Dependent Thalassemia Patients? A retrospective study. Splenectomy in Hypothyroidism of TDT patients

  Christos KATTAMIS, Myrto Skafida, Christalena Sofocleous, Antonis Kattamis

  e2019064

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.064

  1192

  PDF: 920

  HTML: 301

• HEMATOPOIETIC STEM CELL TRNSPLANTATION IN THALASSEMIA AND RELATED DISORDERS

  Emanuele Angelucci, Federica Pilo, Clara Targhetta, Martina Pettinau, Cristina Depau, Claudia Cogoni, Sara Usai, Mario Pani, Laura Dessì, Donatella Baronciani

  e2009015

  1387

  PDF: 487

  HTML: 3951

• PATHOPHISIOLOGY OF SICKLE CELL DISEASE AND NEW DRUGS FOR THE TREATMENT

  Lucia De Franceschi

  e2009024

  2009-12-26

  1046

  PDF: 649

  HTML: 11072

• Anti-mullerian hormone evaluates ovarian function in patients with non-transfusion-dependent thalassemia

  Yan Li, Kun Yang, Yali Zhou, Shiwu Cheng

  e2025007

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.007

  1248

  PDF: 1183

  HTML: 168

• The diagnostic approach to central adrenocortical insufficiency (CAI) in thalassemia

  Vincenzo De Sanctis, Heba Elsedfy, Ashraf T Soliman

  e2016026

  2016-05-01

  https://doi.org/10.4084/mjhid.2016.026

  3089

  PDF: 793

  HTML: 2754

• THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA

  adel abd elhaleim hagag

  e2013065

  2013-11-04

  https://doi.org/10.4084/mjhid.2013.065

  2555

  PDF: 820

  HTML: 14936

  Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 294

• Transfusion-related acute lung injury (TRALI) in two thalassaemia patients caused by the same multiparous blood donor

  George J Kontoghiorghes

  e2017060

  2017-10-18

  https://doi.org/10.4084/mjhid.2017.060

  1991

  PDF: 642

  HTML: 835

• The IMPACT OF SUPEROXIDE DISMUTASE GENETIC POLYMORPHISM (SOD2 VAL16ALA) AND SUPEROXIDE DISMUTASE LEVEL ON DISEASE SEVERITY IN A COHORT OF EGYPTIAN SICKLE CELL DISEASE PATIENTS IN EGYPT SOD and SCD in Egypt

  Mervat Khorshied, Iman A, Shaheen, Yasmeen M.M Selim, Asmaa O. Elshahawy, Ilham Youssry

  e2022037

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.037

  1088

  PDF: 565

  HTML: 392

• Liver iron concentration and liver impairment in relation to serum IGF-1 levels in thalassaemia major patients: A retrospective study

  Vincenzo De Sanctis, Ashraf T Soliman, Giancarlo Candini, Christos Kattamis, Giuseppe Raiola, Heba Elsedfy

  e2015016

  2015-02-13

  https://doi.org/10.4084/mjhid.2015.016

  1577

  PDF: 1021

  HTML: 842

• BONE MINERAL DENSITY AND VITAMIN D RECEPTOR GENETIC VARIANTS IN EGYPTIAN CHILDREN WITH BETA THALASSEMIA ON VITAMIN D SUPPLEMENTATION

  Hadeer A Abbassy, Reham Abdel Haleem Abo Elwafa, Omneya Magdy Omar

  e2019013

  2019-01-01

  https://doi.org/10.4084/mjhid.2019.013

  2226

  PDF: 1214

  HTML: 204

• CLINICAL AND BIOCHEMICAL DATA OF ADULT THALASSEMIA MAJOR PATIENTS (TM) WITH MULTIPLE ENDOCRINE COMPLICATIONS (MEC) VERSUS TM PATIENTS WITH NORMAL ENDOCRINE FUNCTIONS: A RETROSPECTIVE LONG-TERM STUDY (40 YEARS) IN A TERTIARY CARE CENTER IN ITALY

  Vincenzo De Sanctis, Heba Elsedfy

  e2016022

  2016-04-12

  https://doi.org/10.4084/mjhid.2016.022

  3690

  PDF: 1014

  HTML: 3482

• Should every patient with MDS get iron chelation – probably yes.

  Kanjaksha Ghosh, Emanuele Angelucci, Federica Pilo, Kinjalka Ghosh

  e2017055

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.055

  2283

  PDF: 940

  HTML: 366

• LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING

  Jassada Buaboonnam, Chayamon Takpradit, Vip Viprakasit, Nattee Narkbunnam, Nassawee Vathana, Kamon Phuakpet, Kleebsabai Sanpakit, Bunchoo Pongtanakul

  e2021065

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.065

  1113

  PDF: 410

  HTML: 155